Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 360

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 360
---
.

Unrealized losses on financial assets relate to unquoted instruments, the fair value of which is determined using level 2 measurements.

16)Income Tax

Due to the Company’s early stage of development, it is not probable that future taxable profit will be available against which the unused tax losses can be utilized. As a consequence, net deferred tax assets are not recognized.

Management revised comparative balance sheets to offset deferred tax assets and liabilities in application of IAS12.74 for a total amount of € 9.0 8.6 9.4

Summary of related offset deferred tax :

                                                                       Year ended December 31,                                                       
  (in thousands of euro)                                                                  2022                 2023                 2024             
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Deferred tax assets / Tax losses carryforwards                                                    7,476                8,344                8,699  
  Deferred tax assets / Provision for defined benefit obligation                           922                  610                  682             
  Deferred tax assets / Others                                                             170                   52                   34             
  Deferred Tax assets                                                                               8,568                9,006                9,415  
  Deferred tax liabilities / Deferred revenue                                                       7,636                8,233                8,754  
  Deferred tax liabilities / Lease contract (IFRS 16 application)                          651                  553                  500             
  Deferred tax assets / Tax amortization                                                   281                  220                  154             
  Deferred tax liabilities / Other                                                           —                    —                    7             
  Deferred Tax liabilities                                                                          8,568                9,006                9,415  

As of December 31, 2024, the accumulated tax losses carryforwards of Innate Pharma SA were € 536,759 466,153 483,570

F-81

At December 31, 2023, the amount of losses carried forward by Innate Pharma S. A. at December 31, 2022 has been adjusted downwards by € 277.0

As of December 31, 2024, the accumulated tax losses carryforwards of Innate Pharma Inc. was € 16,427 17,066 14,198 16,446 15,181 16,775 20-year

Accordingly, net deferred tax assets not recognized are :

                                                               Year ended December 31,                                                             
  (in